In Silico Screening and Docking Analysis of a Few Drugs against Proteins Expressed in Colon Cancer

Colon cancer claims the third rank in the list of most common cancers diagnosed in the United States. Literature findings suggest that certain proteins are highly expressed in a specific type of cancer. Therefore, there is a need to discover drugs that are specific against specific proteins in colon...

Full description

Saved in:
Bibliographic Details
Published in:International journal for research in applied science and engineering technology 2024-01, Vol.12 (1), p.25-29
Main Authors: Kandisa, Ravi Vital, Sai, Todupunuri Varun, Teja, Dr. Rangisetti Naga Prudhvi
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Colon cancer claims the third rank in the list of most common cancers diagnosed in the United States. Literature findings suggest that certain proteins are highly expressed in a specific type of cancer. Therefore, there is a need to discover drugs that are specific against specific proteins in colon cancer. However, most of the anti-cancer drugs in the market are known to exhibit severe side effects. Hence new molecules with maximal efficiency of binding towards proteins expressed in colon cancer would be an advantage. In this study, a novel approach has been implemented to screen the existing drugs in the market versus highly expressed proteins in colon cancer and apoptosis. This study revealed five drugs, such as Olmesartan, Verteporfin, Ritonavir, Telmisartan, and Eprosartan respectively as probable anti-cancer agents based on the molecular dock scores obtained when compared with bounds ligands of each protein.
ISSN:2321-9653
2321-9653
DOI:10.22214/ijraset.2024.57850